Akebia Therapeutics (AKBA) Receives “Buy” Rating from Mizuho

Akebia Therapeutics (NASDAQ:AKBA)‘s stock had its “buy” rating reissued by equities researchers at Mizuho in a research report issued on Tuesday. They presently have a $24.00 target price on the biopharmaceutical company’s stock. Mizuho’s target price points to a potential upside of 66.09% from the company’s previous close.

The analysts wrote, “We had a chance to catch up with CEO John Butler yesterday at the Bio CEO & Investor Conference. We summarize our key takeaways below. Akebia also provided an update on the Vadadustat development program yesterday morning including an expansion of the ongoing phase 2 For2ward and phase 3 Trilo2gy trials in collaboration with Otsuka (TYO:4578, Non rated). While this will delay the timeline for topline data in both programs, we see it as a positive overall as the company will now incorporate additional relevant endpoints with a greater number of patients for better positioning in commercialization. The timeline for data-readouts in the two pivotal Pro2tect and Inno2vate trials remains unchanged.””

Several other research firms also recently commented on AKBA. Piper Jaffray Companies started coverage on Akebia Therapeutics in a research note on Monday, December 18th. They set an “overweight” rating and a $26.00 price objective for the company. ValuEngine downgraded Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Zacks Investment Research raised Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a research note on Monday, November 13th. BTIG Research started coverage on Akebia Therapeutics in a research note on Thursday, December 7th. They set a “buy” rating and a $30.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $24.00 price objective on shares of Akebia Therapeutics in a research note on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $22.20.

Shares of Akebia Therapeutics (AKBA) opened at $14.45 on Tuesday. The company has a market capitalization of $666.97, a P/E ratio of -4.57 and a beta of 0.79. Akebia Therapeutics has a one year low of $8.58 and a one year high of $20.25.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Macquarie Group Ltd. acquired a new position in Akebia Therapeutics during the 3rd quarter worth approximately $183,000. Campbell & CO Investment Adviser LLC acquired a new position in Akebia Therapeutics during the 3rd quarter worth approximately $200,000. Cubist Systematic Strategies LLC acquired a new position in Akebia Therapeutics during the 2nd quarter worth approximately $159,000. Caxton Associates LP acquired a new position in Akebia Therapeutics during the 3rd quarter worth approximately $246,000. Finally, Teacher Retirement System of Texas acquired a new position in Akebia Therapeutics during the 4th quarter worth approximately $188,000. Institutional investors own 62.16% of the company’s stock.

WARNING: “Akebia Therapeutics (AKBA) Receives “Buy” Rating from Mizuho” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/02/13/akebia-therapeutics-akba-receives-buy-rating-from-mizuho.html.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply